TCGX Acquisition Corp. (TCGX) Stock Price

10.05 ▲ +0.01 (+0.10%)
Open: 10.05 Vol: 73.38K Day's range: 10.01 - 10.05 Nov 09, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
TCGX Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 10.03▼ 10.03▼ 10.03▼ 10.04▲ 10.51▼
MA10 10.05▼ 10.05▼ 10.05▼ 10.05▲ 12.00▼
MA20 10.07▼ 10.07▼ 10.08▼ 10.53▼ N/A    
MA50 10.09▼ 10.07▼ 10.23▼ 12.35▼ N/A    
MA100 10.07▼ 11.10▼ 12.00▼ N/A     N/A    
MA200 11.42▼ 12.52▼ N/A     N/A     N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.007▼ -0.001▼ 0.027▲ 0.094▲ N/A    
RSI 37.262▼ 38.333▼ 38.459▼ 29.438▼ N/A    
STOCH 10.714▼ 10.714▼ 10.208▼ 18.963▼ N/A    
WILL %R -100.000▼ -100.000▼ -100.000▼ -70.000     -98.335▼
CCI -98.246     -98.246     -96.175     -46.963     -119.306▼
Latest Filters Detected On TCGX
CDL $TCGX Hanging Man Candlestick Pattern Detected Set Alert
CDL $TCGX Doji Candlestick Pattern Detected Set Alert
TCGX Acquisition Corp. News
TriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of Directors
Monday, November 09, 2026 08:05 AM
(Nasdaq: TCGX) (“TCGX”), a publicly listed special purpose acquisition company, today announced that Daniel Lynch has been appointed Chairman of the TriGemX Bio Board of Directors (the “Board”). Mr.
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for ...
Friday, November 06, 2026 04:00 PM
Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 million TriGemX Bio, a biotechnology company focused ...
TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Monday, November 02, 2026 03:00 AM
TriGemX Bio, Inc. ("TriGemX Bio"), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX) ("TCGX"), a ...
TCGX historical stock data
date open high low close volume
09/11/26 10.05 10.05 10.01 10.05 73,377
06/11/26 10.025 10.04 10.025 10.04 2,405
05/11/26 10.03 10.0301 10.01 10.03 122,800
04/11/26 10.05 10.06 10.02 10.04 54,100
03/11/26 10.03 10.045 10.025 10.03 13,972
02/11/26 10.03 10.08 10.02 10.03 18,839
30/10/26 10.08 10.08 10.02 10.035 47,669
29/10/26 10.10 10.10 10.05 10.06 132,292
28/10/26 10.08 10.12 10.07 10.085 35,398
27/10/26 10.14 10.17 10.05 10.10 423,479
Quote Details
52wk Low:9.90
52wk High:18.91
Vol:73.38K
Avg Vol(3m):1.9M
1Y Chng:+0.00%
1M Chng:-24.83%
Add to Watch List
More Information
Index N/A
Market Cap. 113.49M